Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Citi
Daiichi Sankyo
Fuji
UBS
Colorcon

Generated: March 22, 2019

DrugPatentWatch Database Preview

Litigation Details for AstraZeneca Pharmaceuticals LP v. Sun Pharmaceutical Industries Ltd. (D. Del. 2007)

« Back to Dashboard

AstraZeneca Pharmaceuticals LP v. Sun Pharmaceutical Industries Ltd. (D. Del. 2007)

Docket ➤ Try a Free Trial Date Filed 2007-12-11
Court District Court, D. Delaware Date Terminated 2010-07-13
Cause 35:271 Patent Infringement Assigned To Joseph James Farnan Jr.
Jury Demand None Referred To
Parties ASTRAZENECA PHARMACEUTICALS LP; ASTRAZENECA UK LIMITED; CARACO PHARMACEUTICAL LABORATORIES LTD.; IPR PHARMACEUTICALS INC.; PAR PHARMACEUTICAL INC.; SHIONOGI SEIYAKU KABUSHIKI KAISHA; SUN PHARMACEUTICAL INDUSTRIES INC.; SUN PHARMACEUTICAL INDUSTRIES LTD.
Patents 4,231,938; 4,346,227; 6,316,460; RE37,314
Attorneys Adam S. Nadelhaft; Charles B. Klein; Charles E. Lipsey; Colleen Tracy; Dane A. Drobny; Ford F. Farabow; Henry J. Renk; John D. Livingstone; John K. Hsu; John M. Seaman; Kenneth M. Frankel; Mary K. Ferguson; Mary W. Bourke; York M. Faulkner
Link to Docket External link to docket
Small Molecule Drugs cited in AstraZeneca Pharmaceuticals LP v. Sun Pharmaceutical Industries Ltd.
The small molecule drugs covered by the patents cited in this case are ➤ Try a Free Trial , ➤ Try a Free Trial , ➤ Try a Free Trial , and ➤ Try a Free Trial .

Details for AstraZeneca Pharmaceuticals LP v. Sun Pharmaceutical Industries Ltd. (D. Del. 2007)

Date Filed Document No. Description Snippet Link To Document
2009-09-17 167 , P.H.D. RELATED TO INFRINGEMENT OF U.S. PATENT NO. RE37,314 IN REBUTTAL TO EXPERT REPORT OF DR. BRUCE…2007 13 July 2010 1:07-cv-00806-JJF Patent None District Court, D. Delaware External link to document
2009-09-18 168 Defendants’ baseless defense that U.S. Patent No. RE37,314 (“the `314 patent”) is unenforceable due to inequitable… 1 The `314 patent is a reissue of original U-S. Patent No, 5,260,440 (“the `440 patent”). conceal material…committed by Shionogi and its U.S. patent counsel.1 The `314 patent covers the active ingredient, rosuvastatin… United States Patent and Trade`mark Office (“USPTO”) While prosecuting the `440 patent application Neither…including Shionogi’s U.S. patent counsel and current and former members of Shionogi’s Patent Department. The External link to document
2009-09-18 169 reductase, there are known Mevinolin (U.S. Pat. No. 4,231, 938), pravastatin sodium (U.S. Pat No. 4,346,227)…compounds arc represented by Mevinolin (U.S. Pa,tont 4,231,938) having the following structural formula: ` … consideration: (1) U.S. Patent No. 4,868,185 (Chucholowski); (2) U.S. Patent No. 5,925,852 (Kesseler …EXHIBIT 2 <19) United States (12) Reissued Patent (10) Patent Number: llll|l |l|l|l|l l|| lll|| lllll[…Fiied; Aug. 27, 1993 Related U.S. Patent Documents Reissuc of: (64) Patent No.: 5,260,440 lssncd: Nov. 9, External link to document
Date Filed Document No. Description Snippet Link To Document

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Cantor Fitzgerald
Express Scripts
Citi
Baxter
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.